U.S. pharma giant copyright scrapped two experimental weight loss drugs very last calendar year—a once-each day pill, lotiglipron, because of elevated liver enzymes and also a two times-daily pill, danuglipron, as a result of sturdy Unwanted side effects—but CEO Albert Bourla has sta